Medical Condition News

RSS

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

Lab grown muscle cells raise hope for gastric reflux and fecal incontinence

A new study shows that muscle cells grown in the lab can restore an intestine's ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat patients with conditions such as gastric reflux and fecal incontinence.

5 Dec 2009

New Emergency Stroke System ensures patients’ access to effective treatment

Thanks to Los Angeles County's new Emergency Stroke System, individuals who experience a stroke may now be able to more quickly access some of the latest advances in stroke interventions.

5 Dec 2009

Bayer Diabetes Care announces the winners of 'Express Your Simple Win Creativity Contest'

Bayer Diabetes Care today announced the three grand prize winners of Bayer's "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winning video entries submitted by children with diabetes from across the country.

5 Dec 2009

Critical enzyme activity provides new insight into heart disease mechanisms

Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of heart cells.

5 Dec 2009

Oxygen Biotherapeutics commences enrollment in clinical trial of Oxycyte emulsion for TBI

Oxygen Biotherapeutics, Inc. today announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

5 Dec 2009

AES: Progress in epilepsy management not reached millions of people around the world

Substantial progress has been made over the last 15 years in the healthcare community's ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy management has not reached most of the 50 million people around the world, including many of the nearly three million people in the United States who have the disorder.

5 Dec 2009

Licensing agreement to develop and commercialize potential treatment for Gaucher’s disease signed

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Protalix (NYSE-Amex: PLX), a leading biopharmaceutical company, in its licensing agreement with Pfizer Inc. to develop and commercialize a potential treatment for Gaucher’s disease, a genetic disorder.

5 Dec 2009

Patients new to chronic disease medication face risk of medication discontinuation, finds study

In a new study published online today by Clinical Therapeutics, researchers from Adheris, Inc., an inVentiv Health company, found that patients new to chronic disease medication face the greatest risk of medication discontinuation during the first 30 days of treatment—with rates of discontinuation ranging from 29.6% to 78.1%.

5 Dec 2009

Call for every health insurance plan to cover Phenylketonuria

Credit Senators John Kerry (D-MA) and Robert Casey (D-PA) with a significant contribution to the health care debate: a bill ends a glaring disparity in the way Americans living with Phenylketonuria (PKU) control their potentially devastating disease, and the way others living with serious chronic conditions are treated. "The Medical Foods Equity Act of 2009" aims to save affected families thousands of dollars in out-of-pocket costs, cut long-term costs for the entire system, and offer 20,000 Americans a better shot at healthy, happy, and productive lives.

5 Dec 2009

Late recurrence of Ewing sarcomas and astrocytomas: A risk for some pediatric cancers

Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the National Cancer Institute.

5 Dec 2009

Taro Pharmaceutical Industries' non-sedating barbiturate compound study granted FDA IND exemption

Taro Pharmaceutical Industries Ltd. announced that it has been granted an Investigational New Drug (“IND”) exemption by the United States Food and Drug Administration, (“FDA”), to permit clinical studies on T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid), one of a class of non-sedating barbiturate compounds currently in development by the Company.

5 Dec 2009

Mobile phone does not increase risk of brain tumour

A new study has found no increase in the incidence of brain tumours during the years immediately following the introduction of mobile phones in Nordic countries.

5 Dec 2009

New diagnostic guidelines for inexpensive and accurate detection of lung cancer

A simple, inexpensive computer tool that measures volume changes in the size of suspicious nodules in the lungs picked up by a CT scanner can rule out non-cancerous ones with almost perfect accuracy and enable doctors to diagnose true cancers with fewer, less expensive and less invasive tests.

5 Dec 2009

'Twist' gene plays a key role in the development of breast cancer

Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accurately distinguish stem cells that drive aggressive, metastatic breast cancer from other breast cancer cells.

5 Dec 2009

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

The Multiple Myeloma Research Consortium (MMRC) today announced that it has awarded the Dana-Farber Cancer Institute, and its clinical researchers, Kenneth Anderson, MD, and Paul Richardson, MD, with the 2009 MMRC Center of the Year Award.

5 Dec 2009

Statins may help protect stem cell transplant patients from GVHD

Cholesterol-lowering drugs known as statins are among the most prescribed medicines in the U.S. Now a new study by researchers at Fred Hutchinson Cancer Research Center indicates that statins may protect stem cell transplant patients from one of the most serious complications of the life-saving cancer therapy: graft-versus-host disease, or GVHD. The findings are reported in the Nov. 4 first edition of the journal Blood.

5 Dec 2009

Medical Condition News

New treatment options for leukemia and myeloproliferative disorders introduced

Lab grown muscle cells raise hope for gastric reflux and fecal incontinence

New Emergency Stroke System ensures patients’ access to effective treatment

Bayer Diabetes Care announces the winners of 'Express Your Simple Win Creativity Contest'

Critical enzyme activity provides new insight into heart disease mechanisms

Oxygen Biotherapeutics commences enrollment in clinical trial of Oxycyte emulsion for TBI

AES: Progress in epilepsy management not reached millions of people around the world

Licensing agreement to develop and commercialize potential treatment for Gaucher’s disease signed

Patients new to chronic disease medication face risk of medication discontinuation, finds study

Call for every health insurance plan to cover Phenylketonuria

Late recurrence of Ewing sarcomas and astrocytomas: A risk for some pediatric cancers

Taro Pharmaceutical Industries' non-sedating barbiturate compound study granted FDA IND exemption

Mobile phone does not increase risk of brain tumour

New diagnostic guidelines for inexpensive and accurate detection of lung cancer

'Twist' gene plays a key role in the development of breast cancer

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

Statins may help protect stem cell transplant patients from GVHD

NCI awards $55.4 million, multiple-year contract to Fred Hutchinson Cancer Research Center

Health experts address treatment gap in epilepsy management at AES Annual Meeting

New findings shed light on heart attack symptoms

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News